

## The Challenge of Very Early Systemic Sclerosis

To the Editor:

We read with great interest the article by Blaja, *et al*<sup>1</sup> on the challenge of very early systemic sclerosis (SSc). We have been addressing this topic for some years. Actually, VEDOSS (very early diagnosis of systemic sclerosis)<sup>2</sup>, subsequently renamed very early SSc<sup>3</sup>, was proposed before the development of the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria<sup>4</sup>. The careful analysis of these criteria prompted us to emphasize the need to clearly define the boundaries of the condition<sup>5</sup>. In addition, the subsequent detection of an evolution into SSc satisfying criteria<sup>4,9</sup> in only 50% of strictly defined very early/early SSc led to the proposed term *undifferentiated connective tissue disease at risk for SSc* (UCTD-risk-SSc)<sup>6</sup>.

Defining which of the patients satisfying VEDOSS<sup>2</sup> entry criteria already fulfill SSc classification criteria requires a careful assessment of each patient by history, physical examination, and physiologic and imaging investigations<sup>5,6</sup>.

Predicting the evolution into definite SSc by those strictly labeled UCTD-risk-SSc has long been considered an accomplished task<sup>7</sup>. In that regard, based on the disease course of 102 patients, we have developed a weighted score (Table 1)<sup>8</sup>. By receiver-operation characteristic curve analysis, patients with a score at admission  $\geq 2.75$  evolved into SSc, with a sensitivity of 91.3% and a 73.2% specificity.

The analysis of disease evolution in the VEDOSS cohort patients who at enrollment did not fulfill ACR/EULAR criteria for SSc and did not present any manifestation consistent with SSc sine scleroderma<sup>9</sup> might validate or disprove the use of the criteria.




ANTONELLA RICCARDI , MD, Rheumatology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples; ANTONELLA MARCOCCIA , MD, Centro di Riferimento Interdisciplinare, Interdipartimentale per la diagnosi precoce della Sclerodermia, Sandro Pertini Hospital, Rome; GABRIELE VALENTINI , MD, Rheumatology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Address correspondence to Dr. A. Riccardi, Rheumatology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131 Naples, Italy. E-mail: antonellariccardi84@gmail.com

Table 1. Variables independently predictive of development of SSc based on multivariate regression. Relative weight in a 10-point score.

| Variable         | HR    | 95% CI     | p      | Weight |
|------------------|-------|------------|--------|--------|
| Anti-Scl-70      | 11.57 | 3.12–42.88 | 0.0003 | 3.00   |
| ANA $\geq 1:320$ | 6.93  | 1.81–26.51 | 0.0049 | 2.75   |
| Avascular areas  | 5.03  | 1.36–18.59 | 0.0158 | 2.25   |
| ACA              | 3.92  | 1.13–13.59 | 0.0319 | 2.00   |

From Riccardi, *et al*.<sup>8</sup> SSc: systemic sclerosis; anti-Scl-70: anti-DNA topoisomerase I; ANA: antinuclear antibody; ACA: anticentromere antibodies.

## REFERENCES

1. Blaja E, Jordan S, Mihai CM, Dobrota R, Becker MO, Maurer B, et al. The challenge of very early systemic sclerosis: a combination of mild and early disease? *J Rheumatol* 2020 Mar 15 (in press).
2. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al; EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. *Ann Rheum Dis* 2011;70:476–81.
3. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. *Ann Rheum Dis* 2013;72:319–21.
4. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2013;65:2737–47.
5. Valentini G, Marcocchia A, Cuomo G, Iudici M, Vettori S. The concept of early systemic sclerosis following 2013 ACR/EULAR criteria for the classification of systemic sclerosis. *Curr Rheumatol Rev* 2014;10:38–44.
6. Valentini G. Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). *Autoimmun Rev* 2015;14:210–3.
7. Bellando-Randone S, Matucci-Cerinic M. Very early systemic sclerosis. *Best Pract Res Clin Rheumatol* 2019;33:101428.
8. Riccardi A, Marcocchia A, Borgia A, Guastafierro T, Bondanini F, Fasano S, et al. Undifferentiated connective tissue disease at risk of systemic sclerosis: a weighted score to identify patients who will evolve. *Autoimmun Rev* 2019;18:102358.
9. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. *Arthritis Rheum* 2000;43:444–51.

First Release July 15 2020; *J Rheumatol* 2020;47:xxxxx;  
doi:10.3899/jrheum.200345